Hitachi and ThinkCyte, Inc. announced their collaboration for developing an artificial intelligence (AI)-driven cell analysis and sorting system.
Hitachi provides a range of solutions such as automated cell culture technologies to pharmaceutical companies. With cell analysis and sorting system to the value chain, Hitachi continues contributing to cost reductions in the manufacturing of regenerative medicine and cell therapy products.
Also, both companies are promoting collaboration with pharmaceutical companies and research institutes to speed up the development of the system.
ThinkCyte has developed high-throughput image-based cell sorting technology based on the Ghost Cytometry technology by integrating imaging technology, machine learning, and microfluidics. By applying structured illumination to cell imaging, structural information of a single cell can be converted to one-dimensional waveforms for high-throughput data analysis.
This data analysis approach eliminates time-consuming image reconstruction processes. It allows high-throughput image-based single cell sorting, enabling the discrimination of cells. ThinkCyte’s technology can sort cells without labels by employing this new approach in contrast conventional cell sorting methods rely on the use of labels such as cell surface markers for cell sorting.
The global market for regenerative medicine and cell therapy is expected to grow from US$ 5.9 billion in 2020 to US$ 35.4 billion in 2025.
Hitachi and ThinkCyte have initiated a joint development of the AI-driven cell analysis and sorting system based on their respective technologies, expertise, and know-how. By combining ThinkCyte’s high-throughput and high-content label-free single cell sorting technology and Hitachi‘s know-how and capability to producing stably operative instruments on a large scale, the two companies will together develop a reliable system to enable high-speed label-free cell isolation with accuracy, which has been difficult to achieve with the existing cell sorting techniques, and to realize stable, low-cost and large-scale production of cells for regenerative medicine and cell therapy.